Company intelligence / Profile preview

Mytogen

Massachusetts, United Statesmytogen.com ↗

Ownership: Private
Employees: ~75
Development stage: Other

Overview

Mytogen developed a proprietary cell therapy using autologous skeletal muscle-derived myoblasts to treat heart failure and myocardial injury. The company completed Phase I clinical trials demonstrating safety and some evidence of improved cardiac function, with plans to initiate multi-center Phase II studies before being acquired by Advanced Cell Technology in 2007. Over forty patients were treated in early trials, with four independent studies supporting safety. The FDA allowed progression to Phase II based on end-of-Phase I data.

Therapeutic areas: Cardiovascular
Modalities: Cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Mytogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mytogen.

Explore the full profile